KR20200010211A - Pde9 저해제를 포함하는 약제학적 조성물 - Google Patents

Pde9 저해제를 포함하는 약제학적 조성물 Download PDF

Info

Publication number
KR20200010211A
KR20200010211A KR1020197032163A KR20197032163A KR20200010211A KR 20200010211 A KR20200010211 A KR 20200010211A KR 1020197032163 A KR1020197032163 A KR 1020197032163A KR 20197032163 A KR20197032163 A KR 20197032163A KR 20200010211 A KR20200010211 A KR 20200010211A
Authority
KR
South Korea
Prior art keywords
compound
hours
subjects
dose
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197032163A
Other languages
English (en)
Korean (ko)
Inventor
에드가 슈크
로버트 라이
이샤니 사반트 랜드리
바스카 레게
마이 미야모토
사다하루 고타니
간타 호리에
Original Assignee
에자이 알앤드디 매니지먼트 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에자이 알앤드디 매니지먼트 가부시키가이샤 filed Critical 에자이 알앤드디 매니지먼트 가부시키가이샤
Publication of KR20200010211A publication Critical patent/KR20200010211A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020197032163A 2017-06-01 2018-05-30 Pde9 저해제를 포함하는 약제학적 조성물 Ceased KR20200010211A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762513690P 2017-06-01 2017-06-01
US62/513,690 2017-06-01
PCT/JP2018/020643 WO2018221546A1 (en) 2017-06-01 2018-05-30 Pharmaceutical composition comprising pde9 inhibitor

Publications (1)

Publication Number Publication Date
KR20200010211A true KR20200010211A (ko) 2020-01-30

Family

ID=64455959

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197032163A Ceased KR20200010211A (ko) 2017-06-01 2018-05-30 Pde9 저해제를 포함하는 약제학적 조성물

Country Status (12)

Country Link
US (2) US11484502B2 (https=)
EP (1) EP3630113A4 (https=)
JP (1) JP7293129B2 (https=)
KR (1) KR20200010211A (https=)
CN (2) CN116585316A (https=)
AU (1) AU2018276566A1 (https=)
BR (1) BR112019023557A2 (https=)
CA (1) CA3059539A1 (https=)
MX (1) MX2019013198A (https=)
RU (1) RU2019135261A (https=)
SG (1) SG11201909359YA (https=)
WO (1) WO2018221546A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018221550A1 (ja) 2017-06-01 2018-12-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤
RU2019135834A (ru) 2017-06-01 2021-07-13 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Терапевтическое средство для лечения деменции, представляющее собой комбинацию производного пиразолохинолина и донепезила
BR112019023552A2 (pt) 2017-06-01 2020-06-02 Eisai R&D Management Co., Ltd. Agente terapêutico para a demência com corpos de lewy contendo derivado de pirazoloquinolina
WO2023064857A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras
CN120897742A (zh) * 2022-11-15 2025-11-04 福睿德姆生物科学公司 通过抑制9型磷酸二酯酶增强血清素能致幻药物在治疗或预防某些神经精神障碍中的功效
CN119302958B (zh) * 2023-12-01 2025-10-21 郑州大学第一附属医院 含有bay 73-6691或其衍生物的药物制剂在制备治疗脑损伤疾病药物中的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5318759A (en) 1976-08-02 1978-02-21 Nisshin Oil Mills Ltd Method of making fried beancurd
JPH05132484A (ja) 1991-04-26 1993-05-28 Otsuka Pharmaceut Factory Inc ピラゾロキノリン及びピラゾロナフチリジン誘導体
DK0760819T3 (da) 1994-05-24 2000-10-09 Hoffmann La Roche Tricykliske dicarbonylderivater
DE19642591A1 (de) 1996-10-15 1998-04-16 Basf Ag Neue Piperidin-Ketocarbonsäure-Derivate, deren Herstellung und Anwendung
HN2002000317A (es) 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
BR0313262A (pt) 2002-08-07 2005-07-12 Mitsubishi Pharma Corp Compostos de dihidropirazolpiridina
DE10238722A1 (de) * 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE102004004142A1 (de) 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Cyclylmethyl- und 6-Alkylmethyl-substituierte Pyrazolopyrimidine
RU2426734C2 (ru) 2003-10-03 2011-08-20 Зм Инновейтив Пропертиз Компани Пиразолопиридины и их аналоги
WO2005118583A1 (en) 2004-05-28 2005-12-15 Millennium Pharmaceuticals, Inc. 2, 5-dihydro-pyrazolo`4, 3-c!quinolin-4-ones as chk-1 inhibitors
JP2006045118A (ja) 2004-08-04 2006-02-16 Mochida Pharmaceut Co Ltd 新規ピラゾロキノロン誘導体
CA2622605A1 (en) 2005-09-15 2007-03-22 Aska Pharmaceutical Co., Ltd. Heterocycle compound, and production process and application thereof
CN101466365A (zh) 2006-06-09 2009-06-24 惠氏公司 增强认知功能的方法
TW200808741A (en) 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
WO2008072778A1 (ja) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. 尿路系疾患の処置剤
CA2671980C (en) 2006-12-13 2015-05-05 Aska Pharmaceutical Co., Ltd. Quinoxaline derivatives
PT2152712E (pt) 2007-05-11 2012-02-29 Pfizer Compostos amino-heterocíclicos
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
JP5453431B2 (ja) 2008-09-08 2014-03-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピラゾロピリミジン及びｃｎｓ障害の治療のためのそれらの使用
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
WO2010101230A1 (ja) 2009-03-05 2010-09-10 アステラス製薬株式会社 キノキサリン化合物
PE20120505A1 (es) 2009-03-31 2012-05-09 Boehringer Ingelheim Int Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a
SMT201800036T1 (it) 2009-04-13 2018-03-08 Theravance Biopharma R&D Ip Llc Combinazioni di agonisti di recettore 5-ht4 e inibitori di acetilcolinesterasi per il trattamento di disturbi cognitivi
US8880976B2 (en) 2009-09-25 2014-11-04 Stmicroelectronics, Inc. Method and apparatus for encoding LBA information into the parity of a LDPC system
AP2012006631A0 (en) 2010-08-12 2012-12-31 Boehringer Ingelheim Int 6-Cycloalkyl-1, 5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A inhibitors
RS54834B1 (sr) 2010-09-07 2016-10-31 Astellas Pharma Inc Jedinjenja pirazolokvinolina
US20130040971A1 (en) 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
PT2573073E (pt) 2011-09-26 2015-02-05 Sanofi Sa Derivados de pirazoloquinolinona, sua preparação e sua utilização terapêutica
JP6042060B2 (ja) 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用
JP5938299B2 (ja) 2011-10-05 2016-06-22 ダイセルポリマー株式会社 繊維強化樹脂組成物
WO2013051639A1 (ja) 2011-10-07 2013-04-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロキノリン誘導体
EP2982675B1 (en) 2013-04-05 2017-08-16 Eisai R&D Management Co., Ltd. Salt of pyrazoloquinoline derivative, and crystal thereof
CN107847499A (zh) 2015-05-07 2018-03-27 阿速万科学有限责任公司 治疗神经退行性疾病的方法
BR112019023552A2 (pt) 2017-06-01 2020-06-02 Eisai R&D Management Co., Ltd. Agente terapêutico para a demência com corpos de lewy contendo derivado de pirazoloquinolina
RU2019135834A (ru) 2017-06-01 2021-07-13 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Терапевтическое средство для лечения деменции, представляющее собой комбинацию производного пиразолохинолина и донепезила
WO2018221550A1 (ja) 2017-06-01 2018-12-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤

Also Published As

Publication number Publication date
WO2018221546A1 (en) 2018-12-06
CN116585316A (zh) 2023-08-15
SG11201909359YA (en) 2019-11-28
RU2019135261A (ru) 2021-07-09
CA3059539A1 (en) 2018-12-06
JP7293129B2 (ja) 2023-06-19
EP3630113A4 (en) 2021-02-24
JP2020521726A (ja) 2020-07-27
RU2019135261A3 (https=) 2021-09-08
CN110545812A (zh) 2019-12-06
US11484502B2 (en) 2022-11-01
AU2018276566A1 (en) 2019-11-07
BR112019023557A2 (pt) 2020-06-02
US20220378706A1 (en) 2022-12-01
MX2019013198A (es) 2020-01-20
US20200078306A1 (en) 2020-03-12
EP3630113A1 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
KR20200010211A (ko) Pde9 저해제를 포함하는 약제학적 조성물
KR20230145439A (ko) Irak4 분해제 및 이의 용도
EP1741446B1 (en) Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
JP3289928B2 (ja) Ｓ−アデノシル−ｌ−メチオニン塩、５−メチル−テトラヒドロ葉酸、５−ホルミルテトラヒドロ葉酸から成る群から選択される少なくとも１つの化合物を活性成分として含む、ａｉｄｓ患者の神経障害の治療に有効な医薬組成物
JP7765970B2 (ja) ブルトン型チロシンキナーゼ阻害剤を使用したシェーグレン症候群を処置する方法
KR20140054129A (ko) 라퀴니모드와 인터페론-베타의 병용에 의한 다발성 경화증의 치료
JP2025541249A (ja) Ｉｒａｋ４分解剤及びその使用
JP6966840B2 (ja) 神経変性疾患の改善用医薬
CN115103672A (zh) 治疗与皮质性痴呆相关的游荡的方法
CN113274392A (zh) 用于治疗慢性咳嗽的奥维匹坦
US20040006072A1 (en) Sustained-release alprazolam composition
CN104582793A (zh) 用拉喹莫德和氨吡啶的组合治疗多发性硬化症
JP2003531174A (ja) Ｐｄｅ５インヒビターを使用する勃起機能不全に対する毎日の処置
TW202038955A (zh) 用於治療多巴胺性cns病症之ly3154207劑量療法
TW202214217A (zh) 大麻鹼於治療癲癇的用途
CA3165379A1 (en) Methods of treating pseudobulbar affect and other emotional disturbances
RU2721406C1 (ru) Лекарственный комплекс для лечения диабета 2 типа и диабетической дислипидемии
Valsecchi et al. Paliperidone extended-release in the short-and long-term treatment of schizophrenia
AU2011253775A1 (en) Compositions and Methods for Increasing Blood Platelet Levels in Humans
JP2024508860A (ja) 認知機能障害の処置のためのルバダキシスタットの使用
US20220096486A1 (en) Compounds for use in the treatment of adcy5-related dyskinesia
Souza et al. Evaluation of the relative bioavailability between two formulations of olmesartan medoxomil 40mg, in orodispersible tablet form and coated tablet form, in healthy participants of both sexes
ULC et al. Pr MYLAN-VARDENAFIL
WO2016205304A1 (en) Methods of treatment using substituted diaminopyrimidyl compounds
KR20260010409A (ko) 브루톤 티로신 키나아제의 억제제를 이용한 재발성 다발성 경화증의 치료 방법

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191030

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210521

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230807

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240206

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230807

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I